IDRA News Alert Idera Pharmaceuticals (IDRA) 4.04 12/06/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 6, 2014 at 11:18 PM

Idera Pharmaceuticals (IDRA) 4.04 $IDRA

The Biggest Risks For Stocks In 2015?
Leo Kolivakis - Seeking Alpha - Fri Dec 05, 3:07PM CST
Jeff Reeves, editor of InvestorPlace.com, wrote an article for MarketWatch, 10 biggest risks to the stock market in 2015 : It is shaping up to be another great year for stocks, with the S&P 500 up about 12% year-to-date in 2014 after a roughly...
KO: 43.53 (+0.03), XLB: 49.77 (-0.04), XBI: 181.28 (+3.17), IBB: 308.81 (+2.61), TLT: 121.09 (-0.71), GSG: 24.33 (-0.17), VOO: 190.80 (+0.34), PGNX: 7.26 (+0.01), IDRA: 4.04 (-0.02), QQQ: 105.38 (+0.01), XLK: 42.12 (-0.05), IWM: 117.69 (+0.88), CL: 69.37 (-0.08), XLE: 80.28 (-0.97)

Hawaiian Electric and Taser are big market movers
AP - Thu Dec 04, 3:35PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
TSLA: 223.71 (-4.57), HE: 32.78 (+0.56), PLUG: 3.60 (-0.10), CLV: 7.54 (-0.01), CLF: 7.97 (-0.06), BKS: 22.63 (+1.60), ARO: 2.46 (-0.02), RAD: 5.69 (+0.11), CARB: 14.38 (+0.17), SQNM: 3.77 (+0.10), ENB.TO: 58.46 (-1.58), RIG: 18.72 (+0.04), IDRA: 4.04 (-0.02), ANF: 27.29 (-0.61), ENB: 51.15 (-1.65), TASR: 24.82 (+0.67), AVGO: 103.99 (+0.92), PBYI: 205.94 (+10.39)

Traders Get Bullish on Shares of Idera Pharmaceuticals, Shares Up 7.0% (IDRA)
Comtex SmarTrend(R) - Wed Dec 03, 10:36AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's best performing low-priced stocks, up 7.0% to $3.83 on 3.7x average daily volume. Idera Pharmaceuticals has traded 2.7 million shares thus far today, vs. average volume of 727,000 shares per day. The stock has outperformed the Dow (7.0% to the Dow's 0.1%) and outperformed the S&P 500 (7.0% to the S&P's 0.2%) during today's trading.
IDRA: 4.04 (-0.02)

Idera up on preclinical data
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 9:47AM CST

IDRA: 4.04 (-0.02)

Idera Pharmaceuticals Announces Cancer Immunotherapy Regimen With Intratumoral IMO-2055 Demonstrated Potent and Systemic Anti-Tumor Activity in Preclinical Models
GlobeNewswire - Tue Dec 02, 3:30PM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, today announced new preclinical data that showed cancer immunotherapy with intratumoral injections of IMO-2055 and ipilimumab demonstrated potent and systemic anti-tumor activity in multiple preclinical cancer models. IMO-2055 is a synthetic oligonucleotide-based agonist of Toll-like receptor (TLR) 9 discovered and developed by Idera. Ipilimumab is a checkpoint inhibitor targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The data were presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Meeting in Orlando, Fla., earlier today.
IDRA: 4.04 (-0.02)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 11:47AM CST

CY: 13.02 (+0.54), QDEL: 24.95 (+0.94), WLT: 1.73 (-0.05), VNCE: 28.09 (-1.64), ISNS: 4.00 (+0.94), VII: 1.97 (+0.41), NTLS: 4.22 (-0.34), MFRM: 61.61 (-0.46), GSAT: 2.77 (+0.06), MOLG: 2.80 (-0.05), EVOK: 5.82 (-0.11), IDRA: 4.04 (-0.02), SCVL: 23.77 (unch), VGGL: 3.63 (-0.05), MIXT: 7.30 (-0.15), ENVI: 1.25 (unch), REI: 9.11 (-0.23), TRX: 0.86 (-0.02), DGLY: 19.83 (-1.17), CODE: 30.13 (+1.12)

Idera Announces Appointment of Robert A. Doody Jr. as Vice President of Investor Relations and Corporate Communications
GlobeNewswire - Tue Dec 02, 9:50AM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare diseases, announced that it has appointed Robert A. Doody Jr. as Vice President, Investor Relations and Corporate Communications.
IDRA: 4.04 (-0.02)

Idera Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Dec 02, 7:30AM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing novel nucleic acid therapeutics for cancer and rare diseases, today announced that Company management will present at the 26 Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 3:30 p.m. EST in New York.
IDRA: 4.04 (-0.02)

Idera Pharmaceuticals Names Vincent J. Milano Chief Executive Officer
GlobeNewswire - Mon Dec 01, 5:06PM CST
-- Appointment brings commercial, operational and financial expertise
IDRA: 4.04 (-0.02), VNDA: 12.30 (+0.03)

New Chief at Idera
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 3:54PM CST

IDRA: 4.04 (-0.02)

Idera Pharmaceuticals (IDRA) Is Today's Strong On High Volume Stock
at The Street - Fri Nov 28, 9:03AM CST
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a strong on high relative volume candidate
IDRA: 4.04 (-0.02)

Idera Pharmaceuticals: A Star In The Making
Samreen Agha - at Seeking Alpha - Wed Nov 26, 11:46AM CST

IDRA: 4.04 (-0.02)

Hot Stock: Idera Pharmaceuticals, Shares Gain 8.2% (IDRA)
Comtex SmarTrend(R) - Wed Nov 26, 10:05AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's best performing low-priced stocks, up 8.2% to $3.03 on 2.5x average daily volume. Idera Pharmaceuticals has traded 1.7 million shares thus far today, vs. average volume of 665,000 shares per day. The stock has outperformed the Dow (8.2% to the Dow's -0.1%) and outperformed the S&P 500 (8.2% to the S&P's 0.1%) during today's trading.
IDRA: 4.04 (-0.02)

Are Central Banks Panicking?
Leo Kolivakis - Seeking Alpha - Fri Nov 21, 12:50PM CST
Koh Gui Qing and Jason Subler of Reuters report, China surprises with interest rate cut to spur growth : China cut interest rates unexpectedly on Friday, stepping up efforts to support the world's second-biggest economy as it heads towards its...
PGNX: 7.26 (+0.01), BCRX: 10.27 (+0.35), AVNR: 16.99 (+0.03), ACAD: 31.16 (+0.70), IDRA: 4.04 (-0.02), QQQ: 105.38 (+0.01), SGEN: 36.10 (-0.40), XBI: 181.28 (+3.17), TGTX: 13.80 (-0.04), IBB: 308.81 (+2.61), THLD: 3.22 (+0.22), IWM: 117.69 (+0.88), TWTR: 38.49 (-0.30), XOMA: 4.66 (+0.20)

Idera Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Thu Nov 13, 7:30AM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing novel nucleic acid therapeutics for rare diseases, today announced that Company management will present at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 4:10 p.m. EST in New York.
IDRA: 4.04 (-0.02)

Idera Pharmaceuticals' (IDRA) CEO Sudhir Agrawal on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 10:52PM CST

IDRA: 4.04 (-0.02)

Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST

CANF: 4.02 (-0.02), JNJ: 108.51 (+0.95), IDRA: 4.04 (-0.02), DERM: 17.50 (+0.28), MRK: 61.49 (+0.57), PFE: 31.99 (+0.32), AZN: 73.72 (-0.22), AMGN: 169.24 (+2.69), GSK: 46.04 (+0.15), HSP: 60.10 (+0.84), NVS: 95.83 (+0.06), CELG: 114.13 (+0.50)

Idera ups revenues 329% in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:00AM CST

IDRA: 4.04 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mesirow Taps Shawn Beber as New CEO: Strategic Leap

Beber's Big Move: Mesirow Bets on Experience When a company's betting big on its next move, it goes for someone who's seen a storm or two. Enter Shawn Beber. Mesirow's new main guy. The firm isn't playing small potatoes with this hire. Fresh off a long gig at CIBC, Beber brings a hefty bag of tricks and a track record of navigating the high seas, none more impressive than...

Mind Meets Soul: Neuroscience and Spiritual Pathways

The Brain, Stress, and Spiritual Practices Ever tried to meditate and wondered if it actually does a number on your mind? Well, here comes Dr. Helen Lavretsky, who’s delving into the nitty-gritty of what happens up there when stress hits and spirituality steps in. This session on November 10 is bound to be a humdinger in the realm of science-meets-spirit. If you've ever...

WaterField's Starlink Case: Compact Yet Professional

Packing a Punch From Every Angle Listen, I've seen about every bag known to tech warriors, but WaterField's new Starlink Mini Go Case? It's turning some heads in the gizmo storage game. The folks at WaterField Designs, cooking out of San Francisco since '98, have whipped up something here that takes those clunky, military-style cases and swaps them for sleek, professional...

Capitol Pulse Survey Shows Staffers' Radical Shift

Generational Shifts and Ideological Alignments Among Congressional Aides There's no denying it, things are heating up on Capitol Hill—not in chambers, but in the offices. A fresh Capitol Pulse survey is shoving this under the spotlight, dissecting how congressional staffers’ political ideologies stack up against their bosses'. Conducted by CNCT and dissected by...

MPLX Reports Q3 2026 Results with 12.5% Distribution Hike

Another Distribution Hike: 12.5% Bump in Q3 Man, MPLX is at it again, boosting that quarterly distribution by a hefty 12.5%. That's three years running now, marking it up to $4.84 per unit on an annualized basis. In an industry where reliability sometimes feels like a relic, this kind of consistency is a sweet serenade to any income-focused investor's ears. "MPLX is...

Sunrate's Bold Move: New Payment Bond with Netstorming

Sunrate Joins Forces with Netstorming When two industry powerhouses shake hands, it's wise to sit up and listen. Sunrate, the global whiz in payment solutions, has linked arms with Netstorming, a tech-savvy pioneer in the travel sector. This ironclad partnership was announced at World Travel Market London 2026. Owners of travel businesses should take note: things are...

Multiconsult's Q3 2026 Results: A Gradual Rebound

Peering into the Q3 Crystal Ball When a company drops its quarterly results, it's like unveiling a new episode in an ongoing drama, and the Multiconsult ASA (Oslo: MULTI) saga is no exception. In their third quarter of 2026, the performance started to show signs of life following a somewhat sluggish run. While the numbers aren't sky-high, they're a solid indication that...

SRG DocketWatch: Tracking FCC Docs in Real-Time

I'll admit it—sometimes the FCC moves like molasses uphill. But keeping track of what they're up to? That's where the real challenge lies. Summit Ridge Group has tossed a lifeline for anyone who's got skin in the game with their new service, SRG DocketWatch. Why SRG DocketWatch Hits the Mark If you're poking your head into more than a few of those 21,000 FCC...

Saudi Tourism Steals the Spotlight at WTM London 2026

A Glimpse into Saudi's Ambitious Tourism Drive Ever feel like someone just decided to dominate the conversation at a global pow-wow? Well, that's the vibe Saudi Arabia brought to the World Travel Market (WTM) in London for 2026. With His Excellency Ahmed Al-Khateeb making headlines together with a mighty entourage of 37 tourism partners, the message was clear: Saudi...

Goodal Skincare Capitalizes on K-Beauty Craze at Costco

A Venture into American Retail Goodal, the darling of Korea's skincare scene, is staking its claim at Costco. This is no small feat, my friends. We're talkin' about a brand that's carved out a sweet niche with its Green Tangerine line. Now it's hitching its wagon to one of America's retail behemoths, known for its unique knack in beauty products. From Olive Young to...